Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUINTIS: Fruquintinib + Tislelizumab in MSS/pMMR mCRC Without Liver Metastases
NCT06856837Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Oct 2025
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 2 trial of fruquintinib, tislelizumab in metastatic colorectal cancer (mCRC), sponsored by Institut für Klinische Krebsforschung. Started Oct 2025; status: recruiting.
02
Drugs
fruquintinibtislelizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06856837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856837.